All In Biotech

Drug Trial Radar · NCT04336124

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

A Phase I Safety and Pharmacokinetic Study of CVM-1118 Extended-Release Capsules Administered Orally to Patients With Advanced Cancers

Last checked: Nov 19, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

May 25, 2020

Primary completion

Feb 8, 2021

Study completion Apr 8, 2022

Sponsor

Lead sponsor
TaiRx, Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CVM-1118 Immediate-release (IR) Capsule and CVM-1118 Extended-release (ER) Capsule are proprietary oncology products developed by TaiRx, Inc. for the treatment of patients suffering from advanced cancer. Due to the short elimination half-life of CVM-1118 IR capsules, the extended release (ER) formulation, containing mini-tablets in hard capsule, has been developed to prolong the drug absorption and longer exposure after oral administration. The designed dose of CVM-1118 ER was 200 mg per capsule to provide a more patient-compliant and safe dosage of CVM-1118. The clinical study CVMEX-001 is therefore designed to evaluate the safety and pharmacokinetics of CVM-1118 extend release (ER) Capsule (200 mg/capsule) in patients with advanced cancer.

Conditions

  • Advanced Cancer

Interventions

  • CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)Drug

    Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles. Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing. A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day. If 2 or more patients experience a DLT, no further dose escalation will occur.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT) of CVM-1118 ER CapsuleTime frame: up to 28 days
  2. Maximum tolerated dose (MTD) of CVM-1118 ER CapsuleTime frame: up to 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • China Medical University Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.